Skip to content

Advertisement

  • Keynote speaker presentation
  • Open Access

Molecular enhancement of sentinel node evaluation

  • 1
Journal of Translational Medicine201513 (Suppl 1) :K4

https://doi.org/10.1186/1479-5876-13-S1-K4

  • Published:

Keywords

  • Melanoma
  • Sentinel Node
  • Sentinel Node Biopsy
  • Cutaneous Melanoma
  • Lymphatic Mapping

Lymphatic mapping and sentinel node biopsy are widely used to stage and manage patients with intermediate and thicker primary cutaneous melanoma. Likelihood of sentinel node metastases can be estimated from patients’ demography and primary tumor characteristics, but is precisely determined only by microscopic evaluation of excised node(s). Molecular/Genetic techniques, such as RT-PCR, Gene Expression Microarray, detection of metastasis-associated gene signatures and gene sequencing are likely to increase precision in future. Recent 10 year results of Multicenter Selective Lymphadenectomy Trial 1 (MSLT1) [1] confirm that biopsy-based management prolongs disease free survival for all node-positive patients (P=0.01-0.03) and significantly increases 10 year distant disease-free survival (P=0.006) and melanoma-specific survival (P=0.02) for node-positive patients with intermediate thickness primaries. The trial also confirmed very clearly that the presence or absence of sentinel node metastases is best determined by close pathological evaluation of sections from nodal tissues, stained conventionally and by immunohistochemistry (S-100 protein, Mart-1, HMB-45). Patients with sentinel node metastases have a significantly unfavorable outcome that correlates with the amount and disposition of nodal tumor as assessed by microscopy, immunohistochemistry and morphometry [2]. Here again precision will be increased by the parallel application of molecular and genetic tests. The accuracy of appropriate patient assignment to early surgical management will be dramatically increased by the addition of molecular testing, more precisely identifying the patients most likely to respond to standard and evolving therapies

Declarations

Acknowledgment

Studies supported by the US National Institutes of Health: CA 29605

Authors’ Affiliations

(1)
Departments of Pathology, Laboratory Medicine and Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA

References

  1. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Puleo CA, Coventry BJ, Kashani-Sabet M, Smithers BM, Paul E, Kraybill WG, McKinnon JG, Wang HJ, Elashoff R, Faries MB, MSLT Group: Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014, 370 (7): 599-609. 10.1056/NEJMoa1310460.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Cochran AJ, Wen DR, Huang RR, Wang HJ, Elashoff R, Morton DL: Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol. 2004, 17 (7): 747-755. 10.1038/modpathol.3800117.View ArticlePubMedGoogle Scholar

Copyright

Advertisement